Recent studies have demonstrated that certain patterns of DNA methylation could be used as a predictive biomarker in response to PD-1 (programmed-death-1) inhibitors and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors in different cancer types. Here, CTLA4 is linked to cancer.